Results 131 to 140 of about 40,516 (197)

US population-level model of clinical impact of lorlatinib treatment on ALK+ metastatic non-small cell lung cancer outcomes. [PDF]

J Comp Eff Res
Kasle A, Abrahami D, Veenstra D, Morlock R, Ramachandran P, Stansfield L, Mak R.   +6 more
europepmc   +1 more source

Cost-effectiveness of tremelimumab plus durvalumab versus sorafenib for unresectable hepatocellular carcinoma in China: an economic evaluation based on five-year overall survival data from the HIMALAYA trial. [PDF]

Front Public Health
Feng R, Liang P, Wang Y, Li D, Jia H, Zheng Y, Huo L, Lv Q.   +7 more
europepmc   +1 more source

Cost-Effectiveness of Angle-Based Minimally Invasive Glaucoma Surgery (MIGS): A Systematic Review of Economic Evaluations. [PDF]

Med Sci (Basel)
Tan ST, Tan SS, Htoon HM, Perera SA, Wong TT, Man REK.   +5 more
europepmc   +1 more source

Commentary: Recombinant <i>Mycobacterium tuberculosis</i> fusion protein for diagnosis of <i>Mycobacterium tuberculosis</i> infection: a short-term economic evaluation. [PDF]

Front Public Health
Ma C, Li J.
europepmc   +1 more source

A 12-Month Trial-Based Economic Evaluation Comparing Positive Parenting Program (Triple P) and Circle of Security Parenting Program (COSP) Versus Treatment as Usual for Families With Young Children (2-6 Years). [PDF]

J Eval Clin Pract
Tarride JE, Blackhouse G, Harvey-Younis N, Rieder AD, Melendez-Torres GJ, Joshi D, Demy J, MacMillan H, Attard C, Jack SM, Atkinson L, Kimber M, Bennett T, Gonzalez A.   +13 more
europepmc   +1 more source

Cost-Effectiveness and Budget Impact of Cardioform versus Amplatzer and Medical Therapy Alone for Patent Foramen Ovale Closure: A UK Payer Perspective. [PDF]

Clinicoecon Outcomes Res
Bentham JR, Neervoort J, Louwsma T, Wolters LF, Lyon J, Landaas EJ, Nakum M.   +6 more
europepmc   +1 more source

A Cost-Effectiveness Analysis for Treatments of Patients with Early Stage Huntington's Disease in the USA. [PDF]

Pharmacoecon Open
Patil D, Slejko JF, Savitt JM, Mattingly Ii TJ.   +3 more
europepmc   +1 more source

Cost-effectiveness of implementing the National Health Service England Diabetes Prevention Programme in Canada: a modelling study. [PDF]

CMAJ
Gupta N, Valabhji J, McManus E, Rahme E, Campbell JR, Dasgupta K.   +5 more
europepmc   +1 more source

Economic evaluation of six immune checkpoint inhibitor-based first-line therapies for advanced squamous non-small-cell lung cancer: a cost-effectiveness analysis based on network meta-analysis. [PDF]

Front Pharmacol
Qiu Z, Wang G, Lou Y, Xuan F.
europepmc   +1 more source

Cost-utility analysis and budget impact of policy options for kidney replacement therapy coverage for end-stage kidney disease in Kenya. [PDF]

BMJ Open
Nyokabi P, Chaikledkaew U, Thavorncharoensap M, Youngkong S, Mutono N, Ngaruiya G, Thakkinstian A.   +6 more
europepmc   +1 more source